Claims for Patent: 9,844,574

Summary for Patent: 9,844,574

Title:	Cancer treatment using viruses and camptothecins
Abstract:	Mammalian subjects having a neoplasm are treated with a virus and a camptothecin compound, for example irinotecan or topotecan. The virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus. The treatment can also include administration of a monoclonal antibody against epidermal growth factor receptor, for example cetuximab.
Inventor(s):	Lorence; Robert M (Bethesda, MD), Roberts; Michael Scot (Myersville, MD)
Assignee:	Wellstat Biologics Corporation (Rockville, MD)
Application Number:	15/195,200
Patent Claims:	1. A method of treating a mammalian subject having a neoplasm, comprising administering to the subject a Newcastle disease yirus and a camptothecin compound in a combined amount effective to treat the subject. 2. The method of claim 1, further comprising administering to the subject a monoclonal antibody against epidermal growth factor receptor in an amount effective, in combination with the virus and the camptothecin compound, to treat the subject. 3. The method of claim 2, wherein the monoclonal antibody is cetuximab. 4. The method of claim 1, wherein the virus is replication-competent. 5. The method of claim 1, wherein the virus is a mesogenic strain of Newcastle disease virus. 6. The method of claim 1, wherein the virus is administered intravenously. 7. The method of claim 1 wherein the camptothecin compound is selected from the group consisting of topotecan, 9-aminocamptothecin, exatecan, karenitecin, rubitecan, lurtotecan, and a homocamptothecin. 8. The method of claim 1, wherein the camptothecin compound is irinotecan. 9. The method of claim 1, wherein the camptothecin compound and the virus are administered to the subject within a single twenty-four hour period. 10. The method of claim 1, wherein the camptothecin compound is administered from twenty-four hours to one month before administration of the virus. 11. The method of claim 10, wherein the camptothecin compound is administered from twenty-four hours to one week before administration of the virus. 12. The method of claim 1, wherein the camptothecin compound is administered to the subject from twenty-four hours to one month after administration of the virus. 13. The method of claim 12, wherein the camptothecin compound is administered to the subject from twenty-four hours to one week after administration of the virus.

Details for Patent 9,844,574

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2039-02-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2039-02-26